ProShare Advisors
RAPT

ProShare Advisors’s RAPT Therapeutics RAPT Stock Holding History

ProShare Advisors’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,102
Closed -$324K – 2285
2021
Q4 		$324K Sell
1,102
-27
-2% -$7.22K ﹤0.01% 1740
2021
Q3 		$280K Sell
1,129
-16
-1% -$4.23K ﹤0.01% 1598
2021
Q2 		$291K Buy
+1,145
New +$214K ﹤0.01% 1915

Other funds holding RAPT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

ProShare Advisors's RAPT Position: Q1 2022 in Review

ProShare Advisors sold out of RAPT Therapeutics (RAPT) in Q1 2022, closing a stake of 1,102 shares — an estimated $324K sold.

ProShare Advisors first reported a position in RAPT in Q2 2021 and held it in 3 quarters. The position peaked at $324K in Q4 2021. 85 funds tracked by Wall St. Rank hold RAPT as of Q1 2022.

  • ProShare Advisors reported no remaining RAPT Therapeutics position as of Q1 2022 after selling out during the quarter.
  • ProShare Advisors sold 1,102 RAPT Therapeutics shares in Q1 2022, an estimated $324K.
  • ProShare Advisors first reported a position in RAPT Therapeutics in Q2 2021 and held it in 3 quarters.
  • ProShare Advisors's RAPT Therapeutics position peaked at $324K in Q4 2021.
  • 85 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2022.

Based on ProShare Advisors's 13F filing for Q1 2022, filed 10 May 2022.